Danaher (DHR) is back in focus after unveiling a partnership with Microsoft that targets AI powered agentic control of lab instruments and data workflows across multi vendor scientific environments. Recent trading tells a cautious story. Danaher's 1-day share price return declined 3.2%, with the 7-day and 30-day share price returns also down 5.4% and 5.8%. This hints at fading short-term momentum despite a broadly flat 90-day move and a modestly positive 3-year total shareholder return of 1.3%. Scan how Danaher's AI partnership compares with other lab and healthcare leaders by reviewing the hand-picked 35 healthcare AI stocks that are leaning into similar AI driven workflows.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.
